Fmr LLC Boosts Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

FMR LLC grew its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,109,141 shares of the company's stock after purchasing an additional 282,301 shares during the quarter. FMR LLC owned approximately 7.89% of Kymera Therapeutics worth $241,816,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Massachusetts Financial Services Co. MA increased its position in shares of Kymera Therapeutics by 11.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company's stock valued at $21,458,000 after acquiring an additional 47,507 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Kymera Therapeutics by 19.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock valued at $4,663,000 after purchasing an additional 25,317 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Kymera Therapeutics during the 2nd quarter worth $4,271,000. E Fund Management Co. Ltd. boosted its holdings in shares of Kymera Therapeutics by 391.2% in the 2nd quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company's stock worth $1,461,000 after buying an additional 38,981 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Kymera Therapeutics during the second quarter worth about $1,910,000.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Stock Up 3.2 %

Shares of NASDAQ KYMR traded up $1.49 on Monday, reaching $48.34. 246,385 shares of the company's stock traded hands, compared to its average volume of 583,967. The business's 50 day simple moving average is $46.82 and its two-hundred day simple moving average is $42.26. Kymera Therapeutics, Inc. has a 12 month low of $20.32 and a 12 month high of $53.27. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -20.02 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm's quarterly revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.90) earnings per share. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent research reports. Leerink Partnrs raised Kymera Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. Truist Financial reaffirmed a "buy" rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Morgan Stanley increased their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 6th. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $38.00 to $57.00 in a research report on Monday. Finally, Leerink Partners restated an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $53.40.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.